Immunoglobulin E and bullous pemphigoid

被引:37
|
作者
Cozzani, Emanuele [1 ]
Gasparini, Giulia [1 ]
Di Zenzo, Giovanni [2 ]
Parodi, Aurora [1 ]
机构
[1] Univ Genoa, Di S Sal, Dermatol Sect, San Martino Policlin Hosp, I-16132 Genoa, Italy
[2] IDI IRCCS, Mol & Cell Biol Lab, Fdn Luigi Maria Monti, Rome, Italy
关键词
bullous pemphigoid; Th2; anti-BP230 and anti-BP180 IgE; omalizumab; FC-EPSILON-RI; LINKED-IMMUNOSORBENT-ASSAY; MEMBRANE ZONE ANTIBODIES; SERUM IGE LEVELS; BLISTER FLUID; MAST-CELLS; DISEASE-ACTIVITY; AUTOIMMUNE-DISEASE; CIRCULATING IGE; ELEVATED LEVELS;
D O I
10.1684/ejd.2018.3366
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Clinical features and histological findings in bullous pemphigoid (BP) suggest a Th2-oriented inflammatory reaction, especially in the early stages of the disease. Elevated total serum IgE levels, blood eosinophilia, and elevated serum levels of different soluble inflammatory Th2 response mediators have been described in large cohorts of patients with classic clear-cut BP manifestations. Direct immunofluorescence, indirect immunofluorescence, and anti-BP230 and anti-BP180 IgE ELISA testing show self-reactive IgE autoantibodies in a consistent number of BP patients. Both IgE autoantibodies and a Th2-oriented immune response may play a role in the initial phases of BP and atypical cases of BP, such as severe erythematous and urticarial forms of BP, as well as blister formation. Two recently reported experimental murine models employing IgE autoantibodies against BP180 have been reported and the successful treatment of bullous pemphigoid with the anti-IgE antibody, omalizumab, supports the roles played by IgE autoantibodies in BP pathogenesis.
引用
收藏
页码:440 / 448
页数:9
相关论文
共 50 条
  • [31] Bullous Pemphigoid
    Ladizinski, Barry
    Lee, Kachiu Cecelia
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 (05) : 733 - 733
  • [32] Bullous Pemphigoid
    Barry Ladizinski
    Kachiu Cecelia Lee
    Journal of General Internal Medicine, 2013, 28 : 733 - 733
  • [33] The Role of Eosinophils in Bullous Pemphigoid: A Developing Model of Eosinophil Pathogenicity in Mucocutaneous Disease
    Amber, Kyle T.
    Valdebran, Manuel
    Kridin, Khalaf
    Grando, Sergei A.
    FRONTIERS IN MEDICINE, 2018, 5
  • [34] Targeting type 2 inflammation in bullous pemphigoid: current and emerging therapeutic approaches
    Toh, Wu Han
    Lee, Hua-En
    Chen, Chun-Bing
    FRONTIERS IN MEDICINE, 2023, 10
  • [35] Effects of Omalizumab on FcεRI and IgE Expression in Lesional Skin of Bullous Pemphigoid
    Jafari, S. Morteza Seyed
    Gadaldi, Karolina
    Feldmeyer, Laurence
    Yawalkar, Nikhil
    Borradori, Luca
    Schlapbach, Christoph
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [36] Emerging Biomarkers and Therapeutic Strategies for Refractory Bullous Pemphigoid
    Zhou, Tong
    Peng, Bin
    Geng, Songmei
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [37] High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid
    Gaitanis, Georgios
    Alexis, Ioannis
    Pelidou, Sygkliti-Henrietta
    Gazi, Irene F.
    Kyritsis, Athanasios P.
    Elisaf, Moses S.
    Bassukas, Ioannis D.
    EUROPEAN JOURNAL OF DERMATOLOGY, 2012, 22 (03) : 363 - 369
  • [38] Bullous scabies mimicking bullous pemphigoid
    Brar, BK
    Pall, A
    Gupta, RR
    JOURNAL OF DERMATOLOGY, 2003, 30 (09) : 694 - 696
  • [39] Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy
    Zhang, Luyao
    Chen, Zihua
    Wang, Lanting
    Luo, Xiaoqun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [40] What's new in bullous pemphigoid
    Ujiie, Hideyuki
    Shibaki, Akihiko
    Nishie, Wataru
    Shimizu, Hiroshi
    JOURNAL OF DERMATOLOGY, 2010, 37 (03) : 194 - 204